title: Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.
abstract: Anthracyclines, including doxorubicin, epirubicin, daunorubicin and aclarubicin, are widely used as chemotherapeutic agents in the treatment of hematologic and solid tumor, including acute leukemia, lymphoma, breast cancer, gastric cancer, soft tissue sarcomas and ovarian cancer. In the cancer treatment, anthracyclines also can be combined with other chemotherapies and molecular-targeted drugs. The combination of anthracyclines with other therapies is usually the first-line treatment. Anthracyclines are effective and potent agents with a broad antitumor spectrum, but may cause adverse reactions, including hair loss, myelotoxicity, as well as cardiotoxicity. We used hematopoietic stimulating factors to control the myelotoxicity, such as G-CSF, EPO and TPO. However, the cardiotoxicity is the most serious side effect of anthracyclines. Clinical research and practical observations indicated that the cardiotoxicity of anthracyclines is commonly progressive and irreversible. Especially to those patients who have the first time use of anthracyclines, the damage is common. Therefore, early detection and prevention of anthracyclines induced cardiotoxicity are particularly important and has already aroused more attention in clinic. By literature review, we reviewed the research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.
authors: Second Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University 277# West Yanta Road, Xi'an 710061, shaanxi, China.
authors: Jing
authors: J
authors: Zhang
authors: Second Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University 277# West Yanta Road, Xi'an 710061, shaanxi, China.
authors: Xiaohai
authors: X
authors: Cui
authors: Second Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University 277# West Yanta Road, Xi'an 710061, shaanxi, China.
authors: Yan
authors: Y
authors: Yan
authors: Second Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University 277# West Yanta Road, Xi'an 710061, shaanxi, China.
authors: Min
authors: M
authors: Li
authors: Second Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University 277# West Yanta Road, Xi'an 710061, shaanxi, China.
authors: Ya
authors: Y
authors: Yang
authors: Second Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University 277# West Yanta Road, Xi'an 710061, shaanxi, China.
authors: Jiansheng
authors: J
authors: Wang
authors: Second Department of Thoracic Surgery, First Affiliated Hospital, Xi'an Jiaotong University 277# West Yanta Road, Xi'an 710061, shaanxi, China.
authors: Jia
authors: J
authors: Zhang
keywords: Anthracycline; cardioprotective agents; cardiotoxicity; prevention